Recent management of primary retroperitoneal sarcomas shows improved survival rates over time.

• 5-year overall survival increased from 61.7% (2002-2011) to 78.8% (2012-2021).
• Distant metastases rates decreased in the recent cohort (HR 1.50).

These findings influence patient selection and highlight the need to adopt newer treatment strategies to enhance outcomes.

• 30-month post-recurrence survival rose dramatically from 41.9% to 65.9%.